Enhanced APPAMP Compounds and Delivery Systems for Cancer Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept introduces direct improvements and enhancements to the original APPAMP compounds, focusing on novel delivery systems, combination therapies, and improved manufacturing processes to enhance efficacy, safety, and efficiency in cancer treatment.
Background and Problem Solved
The original APPAMP compounds, disclosed in the patent application 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors, demonstrated promising anti-cancer properties. However, the existing patent has limitations in terms of delivery, bioavailability, and manufacturing processes. This inventive concept addresses these limitations by introducing controlled-release matrices, biodegradable polymers, combination therapies, and novel crystalline forms to improve the overall treatment outcomes.
Detailed Description of the Inventive Concept
The inventive concept comprises five distinct aspects: (1) a system for delivering APPAMP compounds using controlled-release matrices and biodegradable polymers, ensuring a predetermined rate of release; (2) a method for treating cancer by combining APPAMP compounds with chemotherapy agents to enhance efficacy; (3) a pharmaceutical composition incorporating APPAMP compounds and cyclodextrin to improve solubility; (4) a novel crystalline form of APPAMP compounds characterized by specific X-ray diffraction patterns; and (5) an improved process for preparing APPAMP compounds involving enzymatic resolution to enhance yield and purity. These innovations collectively improve the safety, efficacy, and efficiency of APPAMP compounds in cancer treatment.
Novelty and Inventive Step
The new claims introduce novel and non-obvious improvements to the original APPAMP compounds, including the use of controlled-release matrices, combination therapies, and novel crystalline forms. The inventive step lies in the identification of these specific limitations and the development of targeted solutions to address them, resulting in a more effective and efficient treatment approach.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include variations in the controlled-release matrix composition, different chemotherapy agents for combination therapy, or alternative solubility enhancers. Additionally, the novel crystalline form could be adapted for use in other pharmaceutical applications, and the enzymatic resolution process could be applied to other compound classes.
Potential Commercial Applications and Market
The enhanced APPAMP compounds and delivery systems have significant commercial potential in the oncology market, with potential applications in various cancer types. The improved manufacturing process and novel crystalline form may also attract interest from pharmaceutical companies seeking to enhance their product portfolios.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically cancer treatment compounds and drug delivery systems, focusing on CDK inhibitors and advanced drug formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical chemist with expertise in medicinal chemistry, drug delivery systems, and cancer treatment technologies, holding a PhD or equivalent advanced degree with 3-5 years of research experience in targeted therapeutic compound development
Obviousness Rationale
A person having ordinary skill in the art would recognize that the published technical disclosure represents predictable variations of the source patent's core APPAMP compounds, utilizing standard pharmaceutical engineering techniques to improve drug delivery, solubility, and therapeutic efficacy. The proposed modifications represent incremental improvements using well-established pharmaceutical formulation strategies that would be apparent to a skilled practitioner seeking to optimize the original compound's performance. These variations demonstrate standard problem-solving approaches in pharmaceutical development that do not require inventive genius but rather systematic application of known methodological improvements.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |